[go: up one dir, main page]

ZA987439B - Methods for treating physiological conditions associated with the use or sequelae of use of cocaine or other pyshomotor stimulants - Google Patents

Methods for treating physiological conditions associated with the use or sequelae of use of cocaine or other pyshomotor stimulants

Info

Publication number
ZA987439B
ZA987439B ZA987439A ZA987439A ZA987439B ZA 987439 B ZA987439 B ZA 987439B ZA 987439 A ZA987439 A ZA 987439A ZA 987439 A ZA987439 A ZA 987439A ZA 987439 B ZA987439 B ZA 987439B
Authority
ZA
South Africa
Prior art keywords
pyshomotor
sequelae
cocaine
stimulants
methods
Prior art date
Application number
ZA987439A
Other languages
English (en)
Inventor
Hyacinth Chi Akunne
Alysia Latrese Green
Ann Elizabeth Corbin
Thomas Gary Heffner
David James Dooley
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22002769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA987439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA987439B publication Critical patent/ZA987439B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA987439A 1997-08-19 1998-08-18 Methods for treating physiological conditions associated with the use or sequelae of use of cocaine or other pyshomotor stimulants ZA987439B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5618997P 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
ZA987439B true ZA987439B (en) 1999-02-26

Family

ID=22002769

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA987439A ZA987439B (en) 1997-08-19 1998-08-18 Methods for treating physiological conditions associated with the use or sequelae of use of cocaine or other pyshomotor stimulants

Country Status (5)

Country Link
US (2) US6194459B1 (fr)
AU (1) AU9019198A (fr)
CO (1) CO4960654A1 (fr)
WO (1) WO1999008667A2 (fr)
ZA (1) ZA987439B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (fr) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
US6359005B1 (en) * 1998-10-16 2002-03-19 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
JP2003503453A (ja) * 1999-07-02 2003-01-28 ワーナー−ランバート・カンパニー 相乗作用組成物：ガバペンチンおよびプレガバリン
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6797707B2 (en) * 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
PL1727620T3 (pl) * 2004-03-12 2007-12-31 Warner Lambert Co C1-symetryczne ligandy bifosfin i ich zastosowanie w asymetrycznej syntezie pregabaliny
BRPI0508998A (pt) * 2004-04-01 2007-09-04 Warner Lambert Co preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica
EA011765B1 (ru) * 2004-06-21 2009-06-30 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Получение прегабалина и родственных соединений
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011141923A2 (fr) 2010-05-14 2011-11-17 Lupin Limited Synthèse améliorée d'un ester alkylique optiquement pur de l'acide (s) - 3-cyano-5-méthyl-hexanoïque, intermédiaire de la (s)-prégabaline
WO2012059797A1 (fr) 2010-11-04 2012-05-10 Lupin Limited Procédé de synthèse de la (s)-prégabaline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE69017302T3 (de) * 1989-08-04 1999-08-05 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid

Also Published As

Publication number Publication date
WO1999008667A2 (fr) 1999-02-25
US6566400B1 (en) 2003-05-20
CO4960654A1 (es) 2000-09-25
AU9019198A (en) 1999-03-08
US6194459B1 (en) 2001-02-27
WO1999008667A3 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
GB9400739D0 (en) Medical clip
EP0741590A4 (fr) Catheter a microballonnet
EP0751767A4 (fr) Guanidines therapeutiques
HUP9904026A3 (en) Use of sibutramine analogues to prevent the development of diabetes
EP0785806A4 (fr) Seringue a usage unique
HU9503451D0 (en) The treatment of small animals
ZA987439B (en) Methods for treating physiological conditions associated with the use or sequelae of use of cocaine or other pyshomotor stimulants
ID22817A (id) Proses pembentukan kembali dengan perlakuan awal katalis
HU9700071D0 (en) Use of muramilpeptides
HUP0102683A3 (en) Coatings agent and the use thereof
ZA973843B (en) Treatment of asthma with TNFR-lg.
GB9404791D0 (en) Third body frictioning
EP0369035A4 (en) Agent for treating pancreatitis or the like
IL149533A0 (en) Treatment of sle with dehydropiandrosterone
EP0755262A4 (fr) Composition de traitement de pneumopathie
HU905325D0 (en) The use of iodine-propargyl-acid-esthers of alpha-amino-derivatives as antimicrobial agent
KR0163053B1 (en) Undersea antifouling agent
GB9726223D0 (en) The treatment of materials
GB9719359D0 (en) The Use of DNA Sequences
EP0872219A4 (fr) Utilisation du spectre de frequences biologiques dans l'embryogenese animale
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
EP0666286A3 (fr) Masses moulables à base d'alliage de polyéther d'aryline et de fibres de carbone.
GB2310804A (en) Modified cannula
GB9611871D0 (en) Improvements for the use of tissues
AU3052P (en) Frahn's Paringa Gem Santalum acuminatum